Table of Content

1. VISTA: An Emerging Immune Checkpoint
1.1 Introduction to VISTA Inhibition
1.2 Structure & Biology Of VISTA Protein
1.3 Mechanism of Action of VISTA Inhibitors
1.4 VISTA Inhibition v/s Conventional Immune Checkpoints Inhibitors


2. Dual Role of VISTA as Inhibitory & Costimulatory Checkpoint
2.1 VISTA as Inhibitory Immune Checkpoint
2.2 VISTA as Costimulatory Checkpoint


3. Significance of VISTA
3.1 Role of VlSTA in Facilitating Cancer Progression
3.2 VISTA as Potential Cancer Biomarker
3.3 VISTA as Therapeutic Target in Autoimmunity


4. Global VISTA Inhibitors Market Trends & Clinical Innovation
4.1 Current Market Scenario
4.2 Future Clinical & Commercialization Opportunities


5. VISTA Targeted Therapies Trends & Clinical Innovation by Indication
5.1 Lung Cancer
5.2 Bladder Cancer
5.3 Colorectal Cancer
5.4 Hematological Cancers
5.5 Autoimmune, Inflammatory, Microbial, & Allergic Disorders


6. VISTA Targeted Therapies Trends & Clinical Innovation By Region
6.1 India
6.2 Australia
6.3 US
6.4 Europe


7. Global VISTA Inhibitors Clinical Trials Overview
7.1 By Country
7.2 By Drug Class
7.3 By Indication
7.4 By Organization
7.5 By Phase


8. Global VISTA Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase
8.1 Preclinical
8.2 Phase - I
8.3 Phase - I/II
8.4 Phase – III


9. Global VISTA Inhibitors Market Dynamics
9.1 Market Drivers & Opportunities
9.2 Market Challenges & Restraints


10. Competitive Landscape
10.1 Adimab
10.2 Aurigene Discovery Technologies
10.3 Curis
10.4 Hummingbird Bioscience
10.5 Kineta
10.6 Korea Drug Development Fund
10.7 Merck
10.8 Pierre Fabre
10.9 PharmAbcine
10.10 Sensei Biotherapeutics



List of Figures

Figure 1-1: VISTA Protein - Structure
Figure 1-2: VISTA - Binding Partners
Figure 1-3: VISTA Inhibition - Basic Mechanism
Figure 1-4: VISTA Inhibition - Edge Over Conventional Checkpoint Inhibition

Figure 4-1: VISTA Inhibitors - Current Market Landscape
Figure 4-2: VISTA Inhibitor – Key Players

Figure 5-1: Pierre Fabre Laboratories - K01401-020 (W0180) Research Study
Figure 5-2: CA-170 - Clinical Trial Insights
Figure 5-3: HMBD-002 Phase I (NCT05082610) Study – Initiation & Completion Year
Figure 5-4: Lung Cancer VISTA Inhibitor – Clinical Landscape
Figure 5-5: Sensei Bio Collaborations
Figure 5-6: SNS-101 Phase I/II (NCT05864144) Study – Initiation & Completion Year
Figure 5-7: Sensei Bio Clinical Pipeline – VISTA Preclinical & Clinical Candidates
Figure 5-8: Cleveland Clinic Research Study for VISTA Inhibitors, May 2024
Figure 5-9: KVA12123 Phase I/II (NCT05708950) Study – Initiation & Completion Year
Figure 5-10: Kineta Q1 Financial Results
Figure 5-11: Aspects Influencing Global VISTA Hematological Market
Figure 5-12: Kings College London & Dartmouth College VISTA Patent
(US10745467B2) – Grant & Expiration Year

Figure 6-1: PMC-309 Phase 1 (NCT05957081) Study – Initiation & Completion Year

Figure 7-1: Global – Number Of VISTA Inhibitors In Clinical Trials By Country, 2024
Figure 7-2: Global – Number Of VISTA Inhibitors In Clinical Trials By Drug Class, 2024
Figure 7-3: Global – Number Of VISTA Inhibitors In Clinical Trials By Indication, 2024
Figure 7-4: Global – Number Of VISTA Inhibitors In Clinical Trials By Organization, 2024
Figure 7-5: Global – Number Of VISTA Inhibitors In Clinical Trials By Phase, 2024

Figure 9-1: Market Drivers & Opportunities
Figure 9-2: Market Challenges & Restraints

List of Tables

Table 5-1: Role of VISTA in Allergic, Autoimmune Disease & Viral Ailments

Table 6-1: US – Ongoing Clinical Trials for VISTA inhibitors

Table 10-1: Curis – VISTA Inhibitors Drugs Clinical Trials Insight
Table 10-2: Curis Merck & Co. – VISTA Inhibitors Drugs Clinical Trials Insight
Table 10-3: Sensei Biotherapeutics – VISTA Inhibitors Drugs Clinical Trials Insight